Clinical Trial Update: Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase I trial update describes safety, tolerability, and pharmacokinetics of a single IM-250 dose in healthy volunteers for herpes simplex virus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Simplex Virus Infection

Drugs mentioned

• IM-250

Snippet

Sponsor: Innovative Molecules GmbH | Conditions: Herpes Simplex Virus | Phase 1 | Status: COMPLETED